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doi:10.1016/j.jtcvs.2006.03.035recent article by Hannan and coworkers1 including almost 60,000 patients
from New York’s cardiac registries forces us to reflect on the reliability of
inferences made from randomized controlled trials (RCTs). The same
pplies to the treatment decisions exclusively derived from findings of RCTs for
atients with coronary heart disease under everyday conditions.
Since the mid-1980s, surgical revascularization has become a standardized
rocedure. Since then, the coronary artery bypass grafting (CABG) technique has
ontinuously improved.2 The superiority of surgical revascularization over medical
herapy was documented at an early stage.3
Since the introduction of percutaneous transluminal coronary angioplasty and
tents, percutaneous coronary intervention (PCI) has become a therapeutic alterna-
ive to medical and surgical therapy in many patients with coronary artery disease.
here has been growing demand for, and use of, PCI because it is less invasive, so
hat today it is carried out 3 times more frequently than coronary surgery.4
Over the last 10 years, numerous prospective RCTs have been conducted to
nswer the question of whether and in what situations CABG or PCI results in a
etter medium- and long-term course. Until very recently, the focus of research has
een exclusively on RCTs and meta-analyses, whereas large population-based
tudies or cardiac registry analyses have received less attention.
The value of stringently conducted RCTs is undisputed because they have great
nternal validity. However, the crucial question is whether their results have rele-
ance to everyday decision making. In RCTs patients are randomly assigned to
tandard and investigational arms and are followed up over a defined period. The
nal results of the randomized groups are often compared, irrespective of whether
he positive result of one treatment arm was induced in part by using the alternative
reatment principle (the intent-to-treat principle) as a result of crossover. Although
he intent-to-treat analysis represents a central tenet of RCTs, it might bias the
esults versus no difference in the context of a comparison of PCI versus CABG.
oreover, it is not an uncommon phenomenon that RCTs are underpowered.5,6
Clearly, even the most thoroughly planned and well-executed investigation might
ail to answer the research question if the sample size is too small. If an underpow-
red study does not find statistically significant differences, it is unclear whether
here is truly no difference between the treatment options or whether the sample size
as prohibitively small to provide sufficient evidence for a statistically significant
ifference.6,7
Finally, patients are usually recruited on the basis of stringent inclusion and
xclusion criteria that are often worryingly dissimilar to the overall patient popu-
ation with coronary artery disease. Meta-analyses8 do not resolve this problem
ecause they are based on those studies just described.
This high degree of patient selection represents the crucial limiting factor in
any randomized clinical trials; the patients included in such studies seldom reflect
he population encountered in routine practice. According to the analysis carried out
y Brett and colleagues,7 many RCTs included markedly less than 10% of all
creened patients. Indeed, patients with common-sense indications for CABG and
ontraindications for PCI (eg, left main stenosis or diffuse, severe 3-vessel diseases)
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Lre often precluded from entering an RCT because the
remise of an RCT is that all patients benefit equally from
oth procedures.
By including a population that is known not to benefit
rom CABG9 and by excluding the complex cases that
redominantly constitute the population undergoing CABG
owadays, these trials were definitely biased against CABG
perations and toward the performance of PCI.10
However, it is striking throughout the literature that the
ean number of grafts–peripheral anastomoses per patient
s usually higher than the mean number of stents per patient.
t can thus be concluded that the criterion “completeness of
evascularization,” which is unquestionably important for
he prognosis, is in fact not achieved as a rule in these highly
elected RCT patient populations.
If the majority of patients are excluded from participat-
ng in RCTs on the basis that they cannot undergo equiva-
ent interventional treatment, it follows that the study results
nd conclusions are exclusively valid for patients with iden-
ical inclusion criteria as those in RCTs. In particular, the
nding that mortality did not increase in patients undergo-
ng PCI compared with in those who had undergone CABG
n these RCTs only applies in a clinical setting to patients
ith profiles included in the study. However, this finding
as often been extended to patients who would actually
ave been excluded from the study according to the RCT
rotocol.
Cohort studies and registry analysis studies try to bridge
his gap in knowledge. Population-based studies attempt to
erive more general conclusions from the results obtained in
 nonselected patient population. Brener and associates11
ompared the clinical course of patients undergoing CABG
ith that of patients undergoing PCI at the Cleveland Med-
cal Center. These patients had been treated with PCI or an
peration, depending on the advice of the managing physi-
ian. With regard to their comorbidity, the groups treated
ith an operation and those treated with PCI differed sig-
ificantly, with the former being more comorbid. PCI was
ssociated with significantly higher mortality rates (risk-
djusted hazard ratio, 2.3; 95% confidence interval, 1.9-
.9). The results of this population investigated intensively
t a single institution have been confirmed in a real-world
tudy by Hannan and coworkers1 by analyzing 59,314 pa-
ients in New York’s cardiac registries who underwent
ither CABG or PCI (all with stents) from 1997 through
000. Risk adjustment was performed by using both multi-
ariable and propensity-score analysis.
The fundamental difference between multivariable and
ropensity-score analysis is that the former adjusts for con-
ounders focusing on the relationship between baseline
haracteristics (eg, age, sex, and comorbidities) and the
utcome (overall survival), whereas propensity-score anal-
sis focuses on the relationship between baseline character- p
The Journal of Thoracic and Cardiovascular Surgery ● July 20stics and the primary predictor variable (CABG vs PCI).
ence propensity-score analysis attempts to reconstruct a
ituation (case matching) similar to randomization.12
The major limitation of observational studies is that both
ropensity-score and multivariable analysis can exclusively
djust for known confounders. Neither propensity-score nor
ultivariable analysis can risk adjust for unobserved or
nknown confounders.12 This represents an important ad-
antage of RCTs that distribute both known and unknown
onfounders equally to both study arms.13 Further limita-
ions of observational studies based on registries might
nclude potential coding errors and missing data.13
In the investigation by Hannan and coworkers,1 patients
ith 2- and 3-vessel disease undergoing CABG had a sig-
ificantly better long-term overall survival, as well as a
ower risk of reintervention, after risk adjustment using both
ultivariable and propensity-score analysis. Interestingly,
n patients with 3-vessel disease, CABG was associated
ith a significantly lower mortality rate compared with that
f PCI, even without risk adjustment. Equivalence with
espect to prognosis between PCI and CABG was found
nly in patients with 2-vessel disease with or without prox-
mal left anterior descending coronary artery involvement in
nadjusted survival analyses.
Overall, PCI was performed in 61% of patients with
ouble-vessel disease, whereas only 42% with proximal left
nterior descending coronary artery disease and 14% with
riple-vessel disease were treated with PCI. On the basis of
hese results, one can conclude that physicians generally
ake good choices for their patients.
The investigation by Hannan and coworkers1 is particu-
arly valuable because it reflects the real-world situation,
eing based on a large and unselected group of patients in
hom the indications for CABG and PCI, respectively,
ere identified as part of a day-to-day routine. This analysis
oes not contradict the large numbers of RCTs comparing
CI versus CABG but applies to a much broader patient
opulation. If patients do not meet the inclusion criteria of
CTs, it seems advisable to decide on therapy by referring
o large registry analyses or cohort studies. Considering the
CTs available today,7 there is essentially no significant
ifference in survival for one of the 2 strategies in the
edium- and long-term course. However, surgical interven-
ion is associated with a significantly lower reintervention
ate, a greatly reduced recurrence of angina, and a higher
ate of complete revascularization.
It is interesting that this synoptic statement is also re-
ected in clinically unselected studies. Van Domburg and
olleagues,14 at the Rotterdam Thorax Center, compared
atient profiles and treatment data, as well as PCI and
ABG outcomes, in the same institution before and after
ntroduction of drug-eluting stents. Despite a much higher
roportion of 3-vessel disease (75% compared with 22%),
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Liabetes (24% compared with 17%), and much worse left
entricular ejection fraction in the CABG group in the
rug-eluting stent era, the mortality of 2.2% within 12
onths after CABG compared favorably with the mortality
f 4.1% in the PCI group.
In summary, only by considering both results from RCTs
nd large cohort studies can real-life clinical situations be
eflected to a degree capable of providing applicable treat-
ent guidelines useful in a daily clinical setting.
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